Was the Vir Biotechnology (VIR) CEO’s share sale a discretionary open-market trade?

No, the CEO’s sale was not discretionary . Footnotes explain the 72,559 shares were sold automatically under a Rule 10b5-1 arrangement to satisfy Vir Biotechnology’s tax withholding obligations from restricted stock unit vesting.

Vir Biotechnology (VIR) CEO auto-sells 72,559 shares to cover RSU tax

Q: What did Vir Biotechnology (VIR) CEO Marianne De Backer report in this Form 4?

Marianne De Backer reported an automatic sale of 72,559 Vir Biotechnology shares at $9.156 each. The filing explains this was to cover tax withholding on vesting restricted stock units under a Rule 10b5-1 arrangement , not a discretionary trade.

Q: How many Vir Biotechnology (VIR) shares does the CEO hold after this transaction?

After the transaction, Marianne De Backer directly owns 948,145 Vir Biotechnology shares . She also indirectly owns 53,118 shares through the Ureel-De Backer Family Trust , where she and her spouse act as trustees, according to the filing.

Q: What role does the Ureel-De Backer Family Trust play in Vir Biotechnology (VIR) holdings?

The Ureel-De Backer Family Trust holds 53,118 Vir Biotechnology shares indirectly for CEO Marianne De Backer. The filing notes that she and her spouse are trustees of this trust, indicating those shares are reported as indirect beneficial ownership.

Q: What is the significance of the Rule 10b5-1 arrangement in this Vir Biotechnology (VIR) filing?

The filing states the sale was under a Rule 10b5-1 arrangement , meaning it followed a pre-set plan. This plan automatically sold 72,559 shares to cover tax withholding on restricted stock unit vesting, reducing the informational weight of the sale’s timing.

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Vir Biotechnology, Inc. President and CEO Marianne De Backer had 72,559 shares of common stock automatically sold on 2026-04-06 at $9.156 per share. The footnotes state this sale occurred under a Rule 10b5-1 arrangement solely to satisfy the company’s tax withholding obligations related to vesting restricted stock units, and did not represent a discretionary trade by her.

After these transactions, she directly holds 948,145 shares of Vir Biotechnology common stock and indirectly holds 53,118 shares through the Ureel-De Backer Family Trust, where she and her spouse serve as trustees.

Insider Trade Summary 10b5-1

Net Seller: 72,559 shares ($664,350)

Net Sell 2 txns

Insider De Backer Marianne

Role President and CEO

Sold 72,559 shs ($664K)

Type	Security	Shares	Price	Value
Sale	Common Stock	72,559	$9.156	$664K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 948,145 shares (Direct); Common Stock — 53,118 shares (Indirect, See Footnote)

Footnotes (1)

Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person. The shares are held in the name of the Ureel-De Backer Family Trust, of which the Reporting Person and her spouse are Trustees.

Key Figures

Shares sold: 72,559 shares Sale price: $9.156 per share Direct holdings after transaction: 948,145 shares +2 more

5 metrics

Shares sold 72,559 shares Automatic sale on 2026-04-06 to cover tax withholding

Sale price $9.156 per share Price for 72,559 Vir Biotechnology common shares

Direct holdings after transaction 948,145 shares Vir Biotechnology common stock directly owned by CEO after sale

Indirect holdings after transaction 53,118 shares Held via Ureel-De Backer Family Trust

Net shares sold 72,559 shares Net-sell direction in transaction summary

Key Terms

Rule 10b5-1 arrangement, restricted stock units, tax withholding obligations, Family Trust, +1 more

5 terms

Rule 10b5-1 arrangement regulatory

"automatic and mandatory sale of shares under a Rule 10b5-1 arrangement"

restricted stock units financial

"in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"to satisfy the Issuer's tax withholding obligations in connection"

Family Trust financial

"held in the name of the Ureel-De Backer Family Trust"

indirect ownership financial

"ownership_type": "indirect""

Form 4 Insider Transactions: What Each Field Means →

04/07/2026 - 04:50 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

De Backer Marianne

(Last)

(First)

(Middle)

C/O VIR BIOTECHNOLOGY, INC.

1800 OWENS STREET, SUITE 900

(Street)

SAN FRANCISCO

CALIFORNIA

94158

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vir Biotechnology, Inc. [ VIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/06/2026		S⁽¹⁾		72,559	D	$9.156	948,145	D
Common Stock								53,118	I	See Footnote⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person.

2. The shares are held in the name of the Ureel-De Backer Family Trust, of which the Reporting Person and her spouse are Trustees.

Remarks:

	/s/ Vanina de Verneuil, Attorney-In-Fact	04/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Vir Biotechnology (VIR) CEO Marianne De Backer report in this Form 4?

Marianne De Backer reported an automatic sale of 72,559 Vir Biotechnology shares at $9.156 each. The filing explains this was to cover tax withholding on vesting restricted stock units under a Rule 10b5-1 arrangement, not a discretionary trade.

How many Vir Biotechnology (VIR) shares does the CEO hold after this transaction?

After the transaction, Marianne De Backer directly owns 948,145 Vir Biotechnology shares. She also indirectly owns 53,118 shares through the Ureel-De Backer Family Trust, where she and her spouse act as trustees, according to the filing.

What role does the Ureel-De Backer Family Trust play in Vir Biotechnology (VIR) holdings?

The Ureel-De Backer Family Trust holds 53,118 Vir Biotechnology shares indirectly for CEO Marianne De Backer. The filing notes that she and her spouse are trustees of this trust, indicating those shares are reported as indirect beneficial ownership.

What is the significance of the Rule 10b5-1 arrangement in this Vir Biotechnology (VIR) filing?

The filing states the sale was under a Rule 10b5-1 arrangement, meaning it followed a pre-set plan. This plan automatically sold 72,559 shares to cover tax withholding on restricted stock unit vesting, reducing the informational weight of the sale’s timing.